A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression
Xavier Sáez‐Llorens(Hospital del Niño), Martin S. Rhee(Gilead Sciences (United States)), Elizabeth Castaño(Dynavax Technologies (United States)), Jaime G. Deville(University of California, Los Angeles), Kirsten White, Aditya H. Gaur(St. Jude Children's Research Hospital), Andrew Cheng(Gilead Sciences (United States)), Steven L. Chuck(Gilead Sciences (United States)), Mobeen H. Rathore, Sarah Arterburn(Gilead Sciences (United States)), Joseph A. Church(University of Southern California), Jeffrey Enejosa(Gilead Sciences (United States)), Dora Estripeaut(Agostino Gemelli University Polyclinic)
Cited by 19
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|847
Lymphocyte subsets in healthy children from birth through 18 years of age
|Journal of Allergy and Clinical Immunology|2003|828